Indianapolis, IN, United States of America

Bradley Earl Reaman



 

Average Co-Inventor Count = 9.0

ph-index = 2

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2018-2020

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Bradley Earl Reaman

Introduction

Bradley Earl Reaman is a notable inventor based in Indianapolis, IN, who has made significant contributions to the field of pharmaceuticals. He holds two patents that focus on novel compounds for treating various types of cancer. His work is particularly relevant in the ongoing fight against this devastating disease.

Latest Patents

Reaman's latest patents include the development of 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer. This invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising these compounds, and methods of using them to treat cancer. The cancers targeted by these compounds include melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, and several others. His second patent also focuses on 2,3-dihydro-1H-indole compounds with similar applications in cancer treatment.

Career Highlights

Reaman is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to contribute to innovative research and development in the pharmaceutical industry. His expertise in the field has positioned him as a valuable asset to the company and the broader scientific community.

Collaborations

Some of Reaman's coworkers include Jolie Anne Bastian and Jiehao Chen, who collaborate with him on various projects related to cancer treatment and pharmaceutical innovations.

Conclusion

Bradley Earl Reaman's contributions to cancer research through his patented inventions highlight the importance of innovation in the pharmaceutical industry. His work continues to pave the way for new treatments that could significantly impact patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…